We partner with the media to inform the public of the global human crisis.
December 12, 2017Indivior Announces NDA Acceptance of RBP-7000 Risperidone Monthly Depot...
November 30, 2017FDA Approves SUBLOCADE™ (Buprenorphine Extended-Release), the First and Only Once-Monthly Injectable Buprenorphine Formulation to Treat Moderate to Severe Opioid Use Disorder...
November 2, 2017Q3 / YTD 2017 Financial Results...
October 31, 2017FDA Advisory Committees Recommend Approval of Indivior’s RBP-6000 for the Treatment of Opioid Use Disorder...
October 3, 2017FDA Posts Advisory Committee Meeting Notice for RBP-6000 NDA...
Global Media Contacts
EMEA, Australasia and China Financial Disclosure Reporting
Disclosure Of Payments, Donations & Joint Working
The Online Press Kit is designed to help media research our company for background information or follow-up stories. Please visit the links below to learn more.
About Indivior PLC – An overview of Indivior, including our worldwide locations and key products
Board of Directors – Biographies of Indivior’s Board
The Indivior PLC Pipeline – Information about the Indivior R&D efforts and progress of medicines in the pipeline